Weeks 24 through 36 showed continued loss but at a decelerating rate
48 Initial evaluation in healthy humans revealed that oral administration of Danuglipron produced a dose-dependent increase in systemic exposure bioavailability
GLP-1RA provides strong and effective glycemic control and also lower body weight and systolic blood pressure
Researchers at UC Irvine issue a warning that GLP-1RAs may be dangerous for children Source: UC Irvine School of Medicine Irvine, CA, August 28, 2023 A team of clinicians, exercise scientists, pharmaceutical scholars, ethicists and behavioral experts at the University of California, Irvine, outlined their concerns that the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) to treat childhood obesity and type 2 diabetes may have unintended and adverse consequences for childrens health
Participants received retatrutide (0.5 mg, 4 mg, 8 mg, or 12 mg), dulaglutide (1.5 mg), or placebo for 36 weeks
interacting medications with anticholinergic effects or those that slow motility can worsen symptoms
